SUVENPHAR — Suven Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹167.94bn
- IN₹161.31bn
- IN₹13.40bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 41.23 | ||
| PEG Ratio (f) | 2.06 | ||
| EPS Growth (f) | 25% | ||
| Dividend Yield (f) | 0.23% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.68 | ||
| Price to Tang. Book | 8.96 | ||
| Price to Free Cashflow | 53.66 | ||
| Price to Sales | 14.38 | ||
| EV to EBITDA | 32.32 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 22.42% | ||
| Return on Equity | 21.57% | ||
| Operating Margin | 38.54% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 3,778.35 | 8,337.9 | 10,097.18 | 13,202.22 | 13,403.29 | 10,795 | 13,003 | 37.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +190.06 | +14.31 | +25.29 | -9.39 | -20.78 | +25 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
Directors
- Venkateswarlu Jasti CHM (72)
- P. Rao CFO
- K. Rao CCO
- Jerry Jeyasingh NED
- J. Ramudu NED
- Vajja Rao IND (68)
- Deepanwita Chattopadhyay NID
- D. Prasad NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 6th, 2018
- Public Since
- March 9th, 2020
- No. of Shareholders
- 72,885
- No. of Employees
- 1,165
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 254,564,956
- Address
- SDE Serene Chambers, HYDERABAD, 500081
- Web
- https://www.suvenpharm.com/
- Phone
- +91 4023549414
- Auditors
- Karvy & Company
Upcoming Events for SUVENPHAR
Q1 2025 Suven Pharmaceuticals Ltd Earnings Release
Similar to SUVENPHAR
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Suven Pharmaceuticals share price?
As of Today at 19:20 UTC, shares in Suven Pharmaceuticals are trading at IN₹659.70. This share price information is delayed by 15 minutes.
How has the Suven Pharmaceuticals share price performed this year?
Shares in Suven Pharmaceuticals last closed at IN₹659.70 and the price had moved by +40.32% over the past 365 days. In terms of relative price strength the Suven Pharmaceuticals share price has outperformed the S&P BSE 100 Index by +7.79% over the past year.
What are the analyst and broker recommendations for Suven Pharmaceuticals?
The overall consensus recommendation for Suven Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Suven Pharmaceuticals dividend yield?
Suven Pharmaceuticals does not currently pay a dividend.
Does Suven Pharmaceuticals pay a dividend?
Suven Pharmaceuticals does not currently pay a dividend.
When does Suven Pharmaceuticals next pay dividends?
Suven Pharmaceuticals does not currently pay a dividend.
How do I buy Suven Pharmaceuticals shares?
To buy shares in Suven Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Suven Pharmaceuticals?
As of the previous close price of IN₹659.70, shares in Suven Pharmaceuticals had a market capitalisation of IN₹167.94bn.
Where are Suven Pharmaceuticals shares listed?
Here are the trading details for Suven Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SUVENPHAR
What kind of share is Suven Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Suven Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Suven Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Suven Pharmaceuticals is IN₹800.00. That is 21.27% above the last closing price of IN₹659.70.
Analysts covering Suven Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of IN₹12.80 for the next financial year.
What is the trend in the Suven Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Suven Pharmaceuticals. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -3.84%.
As of the last closing price of IN₹659.70, shares in Suven Pharmaceuticals were trading +9.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Suven Pharmaceuticals PE Ratio?
The Suven Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 41.23. The shares last closed at IN₹659.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Suven Pharmaceuticals?
Suven Pharmaceuticals' management team is headed by:
- Venkateswarlu Jasti - CHM
- P. Rao - CFO
- K. Rao - CCO
- Jerry Jeyasingh - NED
- J. Ramudu - NED
- Vajja Rao - IND
- Deepanwita Chattopadhyay - NID
- D. Prasad - NID